Entera Bio (ENTX) Operating Expenses (2021 - 2026)

Entera Bio has disclosed Operating Expenses across 6 years of filings, most recently posting $3.5 million for Q1 2026.

• Quarterly Operating Expenses rose 38.08% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (up 23.87% YoY) and the FY2025 annual result came in at $11.5 million, up 20.17% from the prior year.
• Operating Expenses climbed to $3.5 million in Q1 2026, from $3.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $3.8 million in Q1 2022 and troughed at $2.0 million in Q4 2023.
• A 5-year average of $2.7 million and a median of $2.7 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 58.85% — and 2023, when it sank 42.53%.
• Tracing ENTX's Operating Expenses over 5 years: stood at $3.1 million in 2022, then tumbled by 36.14% to $2.0 million in 2023, then rose by 19.05% to $2.3 million in 2024, then surged by 30.17% to $3.0 million in 2025, then climbed by 16.34% to $3.5 million in 2026.
• Business Quant data shows ENTX's Operating Expenses at $3.5 million in Q1 2026, $3.0 million in Q4 2025, and $3.3 million in Q3 2025.